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Cardiovascular diseases (CVD) remain the major cause of death and premature disability in Western societies. Assessing the risk
of CVD is an important aspect in clinical decision-making. Among the growing number of molecules that are studied for their
potential utility as CVDbiomarkers, a lot of attention has been focused on osteoprotegerin (OPG) and its ligands, which are receptor
activator of nuclear factor 𝜅B ligand (RANKL) and TNF-related apoptosis-inducing ligand. Based on the existing literature and on
our experience in this field, here we review what the possible roles of OPG and TRAIL in CVD are and their potential utility as
CVD biomarkers.
1. Introduction
Cardiovascular diseases (CVD) remain the major cause of
death and premature disability in Western societies. In 2013
there were more than 54 million deaths globally and 32% of
them (17 million) were attributable to CVD [1]. Moreover,
current predictions estimate that by the year 2020 cardio-
vascular diseases, notably atherosclerosis, will become the
leading global cause of total disease burden [2]. These figures
reinforce the need for diagnostic-prognostic tools that could
help identify the subset of patients with the highest risk of
morbidity andmortality fromCVD and, therefore, that could
help better tailor/focus our interventions.
Among the growing number ofmolecules that are studied
for their potential utility as CVD biomarkers, much atten-
tion has been focused on osteoprotegerin (OPG) and its
ligands, which are receptor activator of nuclear factor kB
ligand (RANKL) and TNF-related apoptosis-inducing ligand
(TRAIL), as reviewed in [3–6]. OPG is in fact a circulating
glycoprotein, which was first characterized for its ability
to block RANKL and inhibit bone reabsorption, hence its
name. Subsequently, it has been demonstrated that OPG
can inhibit TRAIL peripheral actions, which are related to
cellular life and death, and that it can also have direct (ligand-
independent) effects on the bone, the vasculature, and the
immune system.
While the significance of OPG for vascular biology has
gained epidemiological support [7], with a range of studies
reporting associations between circulating OPG and incident
CVD [8–10], the role and significance of RANKL and TRAIL
are less clear. Recently, Secchiero and colleagues reported that
patients with coronary artery disease displayed an increased
OPG/TRAIL ratio, which was even higher in the subgroup
of patients who developed heart failure, thus suggesting
that the OPG/TRAIL ratio plays a significant role in the
pathophysiology of CVD [11]. Here we review what the
possible roles of OPG and TRAIL in CVD are and their
potential utility as CVD biomarkers.
2. Overview on OPG and TRAIL Biology
2.1. OPG Biology. Osteoprotegerin (OPG) is a protein that
belongs to the tumor necrosis factor (TNF) superfamily,
which was identified by three independent groups [12–14].
Following the observation that when this molecule was
injected into mice it increased their bone mass [15], the
American Society of Bone and Mineral Research Committee
called it osteoprotegerin [16] because it described its bone
protective actions. In humans, OPG is expressed in health
and disease states in a wide variety of tissues [3]. These
include not only the bone [17–19], but also the heart, vessels,
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Figure 1: Representation of the TRAIL/OPG/RANKL system. Osteoprotegerin (OPG) is a secreted glycoprotein, whose predominant and
more bioactive extracellular form is a disulphide-linked dimer. By acting as a decoy receptor for TRAIL and RANKL, OPG regulates many
processes, such as cell apoptosis/survival and necroptosis, immune surveillance and host defence, and bone resorption.Moreover, OPG binds
glycosaminoglycans such as heparin sulfate proteoglycans (HSPG), whereby it regulates monocyte chemotaxis, OPG release, and fibrosis. As
for TRAIL, it is expressed as a transmembrane protein, which can be cleaved and released as a soluble molecule, which combines with two
other molecules of TRAIL to form a trimeric ligand. TRAIL homotrimers bind to their specific receptors, which include two death receptors,
TRAIL-R1 and TRAIL-R2, and three decoy receptors, TRAIL-R3, TRAIL-R4, and osteoprotegerin (OPG). Likewise, RANKL can be found in
both membrane-bound and soluble forms. When it is released as a soluble molecule, RANKL combines with two other molecules of RANKL
to form a trimeric ligand, which binds to its receptor RANK. HSPG is heparin sulfate proteoglycans; OPG is osteoprotegerin; R is receptor;
RANK is receptor activator of nuclear factor kappa-B, RANKL is receptor activator of nuclear factor kappa-B ligand; TRAIL is TNF-related
apoptosis-inducing ligand.
kidney, liver, spleen, thymus, lymph nodes [20], as well as the
adipose tissue, and pancreas [21–23]. In the vessels, OPG is
expressed by endothelial [24] and smooth muscle [25] cells.
The gene encoding for OPG is located on chromosome 8
at position 8q24 [12], in a region that seems to harbor a
gene cluster involved in the regulation of bone development
and metabolism [12]. OPG gene locus spans approximately
29 kb and it has five exonic segments. OPG is expressed
as a circulating glycoprotein of 401 amino acids with seven
structural domains. Among them, domain 7 contains a
heparin-binding region as well as the free cysteine residue
that is required for disulphide bond formation and allows
OPG to interact and combine with another molecule of OPG
to form a dimeric ligand [12]. Therefore, circulating OPG
can be found either as a free monomer of 60 kD or as a
disulphide bond-linked homodimer form of 120 kD, which is
usually biologicallymore active than themonomeric one [12].
Moreover, OPG can also circulate while bound to its ligands,
which are RANKL and TRAIL, as represented in Figure 1.
RANKL and TRAIL are also two members of the TNFR
superfamily of proteins that, in the absence of OPG, usu-
ally bind to specific transmembrane receptors and activate
downstream signaling. On the one hand, by blocking RANKL
[26], which stimulates osteoclast formation and activation
[27], OPG prevents bone loss; this represents the rationale
for its current use in patients with osteoporosis [28, 29].
On the other hand, by blocking TRAIL, OPG prevents
TRAIL-induced apoptosis of tumor cells [30].However, given
that TRAIL induces apoptosis in transformed cells such as
malignant, virally infected, and overactivated cells, while it
spares the normal ones, the actions of TRAIL (and therefore
of OPG-TRAIL) are less well characterized in nontrans-
formed cells. Moreover, OPG may also have direct (ligand-
independent) actions in the vasculature, bone, and immune
system, mediated by its heparin-binding domain [31–33],
which interacts with cellular heparin sulfate proteoglycans
that usually take part in cell-surface signaling [34].
It has to be noted that current enzyme-linked
immunosorbent assays (ELISA) measuring circulating
OPG do not differentiate between its form (monomer
rather than disulphide-linked dimer) and site of origin
[6]. Moreover, OPG can be quantified by different ELISA
(R&D Duoset, BioVendor, and Biomedica) [6], which use
different forms of the molecule as the reference standards
(Figure 2). This results in differences in the lower detection
limits (being 65 pg/mL for R&D Duoset, 115 pg/mL for
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Figure 2: Schematic representation of OPG structural domains as compared to the standards of the available ELISA kits. (a) OPG structural
domains; (b) R&D Duoset ELISA standard; (c) BioVendor ELISA standard; (d) Biomedica ELISA standard. ELISA is for enzyme-linked
immunosorbent assays; OPG is for osteoprotegerin.
BioVendor, and 1.4 pg/mL for Biomedica) as well as in
the final concentrations [35]. Clancy and colleagues [36]
demonstrated that OPG concentrations for the same samples
were significantly different when they were measured by
different assays, while concordance correlation coefficients
for intra- and interassay reproducibility were good.
2.2. TRAIL Biology. As mentioned earlier, TRAIL is also
a protein that belongs to the TNF superfamily and was
cloned on the basis of its high homology to other TNF
family members, such as FasL/CD95L and TNF-𝛼 [37]. The
percentage of identity with FasL/CD95L and TNF-𝛼 is in fact
28% and 23%, respectively. In humans, TRAIL is expressed
in health and disease states in a wide variety of tissues,
including the vessels, where it is expressed in vascular smooth
muscle cells (VSMC) [38]. The gene encoding for TRAIL is
located on chromosome 3 at position 3q26. TRAIL gene locus
spans approximately 20 kb and it has five exonic segments.
In humans, TRAIL is expressed as a type II transmembrane
protein of 281 amino acids. Like TNF-𝛼, TRAIL can be
cleaved at the stalk domain, and by combining with other
two molecules of TRAIL, it forms a circulating homotrimer
with biological activity [39]. As represented in Figure 1, the
human receptors for TRAIL include not only death receptors
(DR) but also decoy receptors (DcR) [40, 41]. TRAIL DR
comprise TRAIL-R1 [42] and TRAIL-R2 [43], which are both
type I transmembrane proteins containing an intracellular
death domain (DD) that classically stimulates apoptosis
upon TRAIL binding and are both expressed in the vessels.
Compared to TRAIL, which is normally expressed by VSMC,
TRAIL-R1 and TRAIL-R2 are also expressed by endothelial
cells (EC) [44–46]. As for TRAIL DcR, they include TRAIL-
R3 [47], TRAIL-R4 [48, 49], and OPG [50]. DcR1 and DcR2
are transmembrane receptors that differ fromDR in that their
cytoplasmatic domain lacks an intact DD, while OPG is a
soluble decoy receptor that is lacking both transmembrane
and cytoplasmatic residues.
In the absence ofOPG,TRAILhomotrimers bindTRAIL-
R1 and TRAIL-R2 on the surface of target cells (Figure 1).
Through such binding, TRAIL is able to trigger cellular
apoptosis in malignant, virally infected, and overactivated
immune cells, hence its acronym. Recently, it has been
shown that TRAIL can also induce necroptosis, which is
a regulated and programmed form of necrosis that takes
place after TRAIL binding to its specific death receptors and
which can be useful to the body when apoptosis has been
blocked [51, 52]. With respect to TRAIL’s ability to induce
apoptosis in tumor cells, studies on TRAIL-knockout mice
have in fact demonstrated that mice without TRAIL are
viable and fertile but more susceptible to tumor metastases,
indicating that TRAIL regulates immune surveillance and
host defence against tumor initiation and progression [53,
54]. In particular, TRAIL seems to mediate the ability of
natural killer cells and cytotoxic T lymphocytes to block
tumor growth andmetastasis development [55]. Interestingly,
one of the unique aspects of TRAIL, as compared to other
proapoptotic ligands [56, 57], is that TRAIL has the ability to
induce apoptosis preferentially in transformed cells, such as
tumor or infected cells, while it spares the normal ones [58].
In particular Ashkenazi and colleagues demonstrated that the
exposure of cynomolgus monkeys to recombinant human-
(rh-) TRAIL at 0.1-10mg/Kg/day over 7 days did not induce
detectable toxicity, whereas, by comparison, TNF-𝛼 induced
severe toxicity at much lower doses such as 0.003mg/Kg/day
[59]. This is the rationale for its use in clinical settings as an
antitumor drug [39].
While it has been clearly demonstrated that TRAIL
induces apoptosis in transformed cells, in nontransformed
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Figure 3: Roles of OPG and TRAIL in atherosclerosis and CVD. In the upper part of the image, summary of the main experimental data
supporting OPG and TRAIL involvement in atherosclerosis. In the lower part of the image, summary of the main clinical data showing
OPG and TRAIL associations with CVD. In the middle, representative image of an aortic atherosclerotic plaque stained by hematoxylin and
eosin (10x original magnification). ACS is acute coronary syndromes; AMI is acute myocardial infarction, and ARBs are angiotensin II type 1
receptor blockers; CAD is coronary artery disease; CKD is chronic kidney disease; CRP is C-reactive protein; DM is diabetes mellitus; OPG
is osteoprotegerin; RAS is renin-angiotensin system; TRAIL is TNF-related apoptosis-inducing ligand; VSMC is vascular smoothmuscle cell.
cells, the actions of TRAIL are less well characterized. For
example, this molecule could actually mediate nonapoptotic
signaling. It has in fact been shown that when TRAIL-
R1 and TRAIL-R2 are activated they not only stimulate
the extrinsic apoptotic pathway, but also may activate sur-
vival/proliferation pathways, such as nuclear factor 𝜅B (NF-
𝜅B), ERK1/ERK2, and Akt [44, 60] (Figure 1). Consistent
with the concept that TRAIL triggers nonapoptotic signals
in normal cells, we have also shown that systemic TRAIL
delivery significantly reduced cardiac fibrosis and apoptosis
in a mouse model of diabetic cardiomyopathy [61]. Potential
mechanisms underlying the ability of TRAIL to activate
such opposed pathways include the redistribution of TRAIL
receptors [62, 63] and the intracellular inhibition of the
apoptotic cascade [64].
3. Role of OPG and TRAIL on Atherosclerosis
3.1. OPG and Atherosclerosis. The current view of atheroscle-
rosis is that it is an inflammatory disease of the vessels [65],
mediated by leukocyte vascular recruitment and migration.
In particular, once different stimuli/forms of injury increase
endothelium adhesiveness to circulating cells, leukocytes
migrate into the subendothelial space promoting lesion initi-
ation, which is usually followed by macrophage recruitment,
VSMC migration and proliferation, fibrous cap formation,
and atherosclerotic plaque development [65]. This process
is generally stimulated by a combination of factors such as
dyslipidemia, hyperglycemia, and shear stress that activate
common pathways, promoting all the events leading to the
development of atherosclerotic plaques. Interestingly, both
OPG and TRAIL are found in atherosclerotic plaques [66],
where they seem to participate in this process by exerting
opposite actions (Figure 3).
As for OPG, the first studies evaluating its effects on
the vasculature indicated that it could protect the vessels
against calcification, given that OPG deficiency resulted in
early-onset severe osteoporosis as well as significant medial
calcification of the aorta and the arteries [67]. Similarly, OPG
inactivation in ApoE-knockout mice resulted in augmented
vascular calcification and increased size of atherosclerotic
plaques, as compared to their controls [68]. However, in
another study where LDLr-knockout mice were fed with an
atherogenic diet and treated with fc-OPG, fc-OPG reduced
plaque calcification but did not affect the number and size of
the lesions, suggesting that although OPG protected against
vascular calcification, it did not affect atherosclerosis progres-
sion and severity [69]. By contrast, our group has shown that
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human full-length OPG induced the proliferation of rodent
vascular smooth muscle cells and increased atherosclerosis
extension in diabetic ApoE-knockout mice, suggesting that
this molecule could actually promote atherosclerosis [70].
Moreover, an infusion of full-length recombinant OPG in
ApoE-knockout mice every 3 weeks for 3 months also
resulted in increased vascular collagen content in the media
[35].
To reconcile these results, it is possible that OPG, ini-
tially secreted to protect the vasculature against calcifica-
tion, would actually damage it by promoting inflammation
and fibrosis. The concept that OPG can actually promote
atherosclerosis development is supported by several in vitro
studies demonstrating that OPG has proinflammatory and
profibrotic effects on the vasculature. As for inflammation, it
has been demonstrated that when leukocyte-endothelial cell
adhesion takes place, it increases the leukocyte production of
proinflammatory cytokines such as TNF-𝛼 and interferon-𝛾,
which would upregulate OPG expression in EC and VSMC
[71–73]. Moreover, in line with the in vitro observation that
OPG stimulates EC expression of adhesionmolecules [73], we
have recently shown that OPG increases leukocyte adhesion
to endothelial cells [74] both in vivo and in vitro, contributing
to atherosclerotic plaque formation. As for vascular fibrosis,
consistent with our earlier finding that human full-length
OPG induced the proliferation of rodent VSMC, we have
found that VSMC treatment with full-length recombinant
OPG induced fibrogenesis with increased expression of
fibronectin, collagen I, collagen III, and collagen IV, as well
as MMP-2 and MMP-9, and TGF-𝛽 [35]. Pretreatment with
the specific TGF-𝛽 receptor inhibitor, prior to treatment with
OPG, attenuatedOPG-induced fibrogenesis and proliferation
in VSMC.These results suggest that OPG is a potent inducer
of fibrogenesis, growth factor synthesis, and proliferation
in VSMC, both in vitro and in vivo, and that its actions
are largely dependent on the autocrine induction of TGF-𝛽,
which itself stimulates OPG in a vicious cycle that results in
the autoinduction of both OPG and TGF-𝛽 [35].
Nevertheless, OPG could also promote atherosclerosis by
stimulating systemic inflammation and the renin-angiotensin
system (RAS) activation, which is one of the most important
pathways leading to atherosclerosis [75, 76]. As for systemic
inflammation, we have recently shown that OPG delivery
increases IL-6, MCP-1, and TNF-𝛼 circulating levels [77],
which is consistent with the view that it takes part in
the pathogenesis of atherosclerosis and CVD by amplifying
inflammation [5]. Consistent with this claim, we have also
reported a positive correlation between OPG and CRP [77].
With respect to the interplay with the RAS, experimental
evidence suggests that there is a mutual stimulatory effect
between OPG and the RAS [35, 78–82]. It has in fact been
demonstrated that angiotensin II (Ang II) increases OPG
expression in human aortic smooth muscle cells [78] as
well as in murine VSMC [35]. Not surprisingly, treatment
with the Ang II type 1 receptor (AT1R) blocker Irbesar-
tan reduced OPG secretion from human abdominal aortic
aneurysm explants [79]. Consistent with this finding, a recent
study has demonstrated that AT1R blockade with Irbesartan
significantly reduced OPG expression in human primary
vascular cells and carotid atheromas [80]. Interestingly, if Ang
II stimulates vascular OPG expression in a dose-dependent
manner, OPG reciprocally stimulates vascular AT1R protein
expression in a dose-dependent manner [81]. Consistent
with this observation, we have observed that OPG delivery
significantly increased ACE and AT1R gene and protein
expression in the pancreas [82], where we hypothesized that
OPG might control their transcription by activating the
mitogen-activated protein kinase signaling [31] that regulates
ACE and AT1R expression.
Interestingly, in addition to RAS blockers, there are other
antiatherosclerotic drugs [83], such as statins and glitazones,
which have exhibited the ability to reduce OPG in the vessels.
As for statins, they reduced TNF-𝛼 and IL-1𝛼-induced OPG
expression in EC and VSMC [84]. As for glitazones, on
the other hand, which are pharmacological PPAR-𝛾 ligands,
they significantly decreased the expression of OPG in human
aortic smooth muscle cells [85].
3.2. TRAIL and Atherosclerosis. Contrary to OPG, ani-
mal studies [86–88] suggest that TRAIL protects against
atherosclerosis. In the first of these studies, TRAIL treatment,
delivered either as soluble recombinant TRAIL by intraperi-
toneal injection or in an adenoviral-vector, significantly
reduced the accumulation and complexity of atherosclerotic
plaques in diabetic ApoE-knockout mice [86]. Here, we
speculated that TRAIL effects were mediated by its ability
to induce apoptosis of infiltrating macrophages within the
plaque, which had been previously observed in vitro by a
different group [89]. The second study was conducted in
TRAIL ApoE-double-knockout mice and demonstrated that
TRAIL deficiency worsened atheromatous lesion formation,
possibly by increasing VSMC content within the plaque
[87]. In the mice lacking TRAIL, there was a reduction in
VSMCapoptosis, indicating that TRAILwould induceVSMC
apoptosis [90] rather than their survival [91] and that this
could be the mechanism protecting against plaque enlarge-
ment. Consistent with our previous findings, Di Bartolo and
colleagues reported a significant increase in atherosclerotic
plaque formation and progression in ApoE- and TRAIL-
double-knockout mice [88]. Here, TRAIL deficiency sig-
nificantly influenced plaque stability, as it increased the
extension of the necrotic core and macrophage infiltration,
while reducing VSMC and collagen content [88]. This work
is of particular interest not only because it confirms TRAIL
antiatherosclerotic effects but also because it sheds light onto
a possible role for TRAIL in glucose metabolism regulation
[92]. Recently, it has also been shown that TRAIL inhibits vas-
cular calcification [93], as TRAIL deficient mice exhibited a
significant increase in tissue RANKL, which leads to vascular
calcification. Consistent with this finding, VSMC exposed to
calcium and TRAIL displayed significantly lower alizarin red
staining (used to quantify vascular calcification) as compared
to those exposed to calcium alone, indicating that TRAIL
protects against calcium-induced VSMC calcification in vitro
[93].
Overall, it is very difficult to draw conclusions on the
mechanisms underlying the antiatherogenic effects of TRAIL
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by simply looking at in vitro data. Potentially, TRAIL is
a molecule with two faces [94], the first that can induce
apoptosis [95] and stimulate inflammation [45, 97] and the
second that can promote cell survival [44, 96] and inhibit
inflammation, depending on its dose and cell responsive-
ness. Nevertheless, animal studies show that TRAIL protects
against atherosclerosis, possibly by inducing apoptosis of
macrophages and VSMC [86–90]. Other potential mech-
anisms underlying TRAIL antiatherogenic effects include
protection of normal vascular cells and anti-inflammatory
actions [44, 92, 98, 99]. As mentioned earlier, both EC
and VSMC express TRAIL receptors and Secchiero and
colleagues have shown that recombinant TRAIL is able to
promote their survival/proliferation by activating intracellu-
lar signaling pathways, such as ERK/MAPK, Akt, andNF-𝜅B,
which are known to promote survival and proliferation [44].
Moreover, the same authors showed that TRAIL upregulates
the production and release of prostanoids, including PGE2
and PGI2, and increases NO production and eNOS activity
in endothelial cells, without activating NF-𝜅B, which are all
involved in the maintenance of vascular homeostasis [98].
It has also been shown that TRAIL counteracts leukocyte
adhesion induced by TNF-𝛼 or IL1-𝛽 by downregulation
of CCL8 and CXCL10 chemokine expression [99]. This is
consistent with the observation that TRAIL can significantly
reduce systemic and tissue inflammation, as assessed by
measuring IL-6, MCP-1, and TNF-𝛼 expression [92], which
on the contrary were found elevated in TRAIL-knockout
mice [88]. Recently, it has also been shown that administra-
tion of human recombinant TRAIL reduced allergic airway
inflammation in a mouse model of asthma [100].
4. Clinical Applications of OPG and TRAIL as
Biomarkers of CVD
4.1. OPG and CVD. Keeping in line with the dichotomy
between the role of OPG and TRAIL in atherosclerosis
(Figure 3), while TRAIL appears to be antiatherosclerotic,
OPG has been shown to be associated with CVD onset and
progression. OPG levels are in fact positively correlated with
markers of vascular damage such as endothelial dysfunction
[101–103], vascular stiffness [104], and coronary calcification
[105], as well as with the presence of coronary artery disease
(CAD) [106, 107]. Consistent with this, OPG has been found
associated with the risk of future CAD in apparently healthy
men and women, independent of established cardiovascular
risk factors [8, 9]. In patients with acute coronary syndromes,
OPG has been linked to the incidence of death, heart
failure (HF) hospitalizations,myocardial infarction (MI), and
stroke [108], which has been successively observed in the
general population as well [109]. Moreover, although initially
it appeared that OPG was an independent risk factor for
incident CVD and vascular mortality but not for mortality
due to nonvascular causes [8, 110], it has been recently
demonstrated that high levels of OPG can also predict
nonvascular mortality [111].
Left ventricular dysfunction is one of the key prognostic
indicators of cardiovascular morbidity and mortality [112].
Interestingly, OPG has been found to be elevated in both
clinical and experimental HF [10].Moreover, different studies
have evaluated the prognostic utility of OPG in patients
with HF. In the first one, Ueland and colleagues showed
that, in patients with history of myocardial infarction and
left ventricular dysfunction, baseline OPG was significantly
higher in those who died from vascular and nonvascular
causes as compared to those who survived [113]. In a subse-
quent study, Omland and colleagues showed that in patients
with acute coronary syndrome the baseline levels of OPG
correlated significantly with the incidence of heart failure
[108]. More recently it has been shown that OPG is predictive
of hospitalization for HF in patients with advanced systolic
HF and ischemic heart disease independently of conventional
risk markers [114].
It is well known that diabetes mellitus and chronic kidney
disease (CKD) are associated with an increased risk of CVD
and vascular mortality [115, 116]. Interestingly, in both condi-
tions OPG levels are elevated and predict CVD onset. Several
groups have reported that OPG levels are elevated in patients
with type 1 and type 2 DM, as reviewed in [6]. Nevertheless,
beside the positive relationship between OPG and type 2
DM, which has been known since 2001 [117], in diabetic
patients there is also a strong association between circulating
levels of OPG and micro- and macrovascular complications
[118, 119]. Here, OPG is associated with cardiovascular events
[119, 120] and the presence and severity of silent myocardial
ischemia [121–124], as well as with the risk of developing end-
stage renal disease [125]. Consistent with the experimental
data showing an inhibitory effect of glitazones on vascular
OPG [85], in type 2 DM patients, pioglitazone was found
to decrease OPG levels [126, 127], which showed correlation
with glucose control [126].
As for CKD, on the other hand, OPG is increased in
patients with nondiabetic [128, 129] and diabetic [119, 125,
130] CKD, where it predicts kidney function deterioration
and vascular events and cardiovascular and all-cause mor-
tality [130]. Consistent with implications in CKD, it has
been recently reported that elevated OPG is associated with
increased 5- and 10-year risk of rapid renal decline, renal
disease hospitalization, and/or deaths in elderly women [131].
4.2. TRAIL and CVD. Contrary to OPG, the serum levels of
TRAIL have been found significantly decreased in patients
affected by or predisposed to CVD. In regard to this issue, it is
notable that serum levels of TRAIL are significantly decreased
in patients with acute myocardial infarction within 24 hours
of admission, compared to healthy controls [132]. Relatedly,
also Michowitz and colleagues found that circulating TRAIL
was significantly lower in patients with acute coronary syn-
drome as compared to those with stable angina or normal
coronary arteries and that it was negatively correlated with
the level of C-reactive protein, which is an independent
predictor of acute vascular events and adverse outcomes
in patients with HF [133]. Given that the same authors
found that TRAIL expression was increased in vulnerable
plaques, where it localized with T cells and oxidized low-
density lipoprotein, they argued that TRAIL decrease in
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patients with CVD might be due to its consumption into
the plaques. Other reasons underlying TRAIL decrease in
patients with acute cardiovascular events might include the
parallel increase in circulating OPG, as well as the increase
of metalloproteinase-2 (MMP-2). While OPG acts as a decoy
receptor for TRAIL, whereby its binding may interfere with
TRAIL dosage explaining TRAIL decrease, the increase in
MMP2 could explain TRAIL decrease as it has been shown
that MMP-2 can induce TRAIL cleavage [134].
Consistent with these findings, circulating TRAIL levels
are inversely associated with an increased risk of CVD
and cardiac mortality [132, 135]. In the work by Secchiero
and colleagues the patients with myocardial infarction who
developed in-hospital adverse clinical outcomes displayed
the lowest levels of TRAIL, indicating that the lower the
level of TRAIL, the higher the risk of HF or death after
myocardial infarction [132]. In the work by Michowitz and
colleagues lowTRAIL levels at dischargewere associatedwith
an increased incidence of cardiac death and heart failure in
the 1-year follow-up [133]. Similarly, an inverse association of
TRAIL levels with mortality was observed in patients with
advanced heart failure [136], as well as in patients with CKD
[137]. Moreover, in older patients (i.e., aged on average 68
years) with cardiovascular diseases, low levels of TRAIL were
associatedwith increased risk of death over a period of 6 years
[135].
5. Conclusions
Experimental studies suggest that there is some dichotomy in
OPG and TRAIL actions, the first being proatherogenic and
the second being antiatherogenic. However, the role of OPG
and TRAIL in atherosclerosis has not been fully understood
yet. It remains unclear whether OPG increase and TRAIL
decrease should be regarded as risk factors rather than risk
markers of CVD; therefore, further studies are needed to
clarify what the pathogenic importance of OPG and TRAIL is
in the process of atherosclerosis. On the other hand, clinical
studies reinforce the view that OPG and TRAIL could be
promising biomarkers of CVD onset and progression. More
evidence (possibly gained after measurement standardiza-
tion) is needed to evaluate the predictive and diagnostic value
of OPG and TRAIL for clinical use.
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